MedPath

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

Not Applicable
Completed
Conditions
Healthy
Registration Number
NCT00347594
Lead Sponsor
Bausch & Lomb Incorporated
Brief Summary

The purpose of this study is to measure the aberrations, corneal surface topography and pachymetry of normal human eyes with the NGDI.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
76
Inclusion Criteria
  • +10.00D to -20.00D of absolute spherical ametropia
  • Must be part of the Bausch & Lomb research clinic
  • Snellen visual acuity must be correctable to 20/25
Exclusion Criteria
  • No more than -6.00D of refractive astigmatism

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Measurement of aberrations with the NGDI and the Zywave II.Single visit
Secondary Outcome Measures
NameTimeMethod
Measurement of corneal topography and pachymetry with the NGDI and the Orbscan IIz.Single visit

Trial Locations

Locations (1)

Bausch & Lomb

🇺🇸

Rochester, New York, United States

Bausch & Lomb
🇺🇸Rochester, New York, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.